Synairgen backer ready to pump £18-£19 million into phase II trial
Portfolio Pulse from
Synairgen PLC plans to raise up to £25 million to fund the development of its investigational inhaled interferon beta treatment, SNG001. The funding includes a significant subscription and a placing and open offer.
December 20, 2024 | 8:15 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Synairgen PLC is raising up to £25 million to fund the development of SNG001, its inhaled interferon beta treatment. This includes a significant subscription and a placing and open offer.
The announcement of a substantial funding round is likely to positively impact Synairgen's stock price in the short term as it secures financial resources for the development of its key product, SNG001. This indicates strong investor confidence and potential progress in its clinical trials.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90